Attached files
file | filename |
---|---|
EX-10.1 - LICENSE AGREEMENT BY AND BETWEEN THE COMPANY AND FIRST WAVE BIO, INC. - AzurRx BioPharma, Inc. | ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 31,
2020
Commission
File Number: 001-37853
AzurRx BioPharma, Inc.
(Exact
name of registrant as specified in its charter.)
Delaware
(State or other
jurisdiction of incorporation or organization)
|
46-4993860
(IRS Employer
Identification No.)
|
1615 South Congress Avenue, Suite 103
Delray Beach, Florida 33445
(Address
of principal executive offices)
646-699-7855
(Registrant's
Telephone number)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Explanatory Note
On
January 4, 2021, AzurRx BioPharma, Inc. (the “Company”)
filed a Current Report on
Form 8-K (the “Prior 8-K”) to report the
Company’s entrance into a license agreement (the
“License Agreement”), dated December 31, 2020, by and
between the Company and First Wave Bio, Inc., a privately-held
Delaware corporation. The Company is filing this amendment to the
Prior 8-K in order to file herewith, as Exhibit 10.1, the License
Agreement. The Prior 8-K otherwise remains unchanged.
Item 9.01 Financial Statements and
Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
License
Agreement, dated December 31, 2020, by and between the Company and
First Wave Bio, Inc.
|
* Certain portions of this exhibit (indicated by
“[*****]”) have been omitted as we have determined (1)
it is not material and (2) is the type that the Company treats
as private or confidential.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
AzurRx BioPharma, Inc.
|
Date:
January 13, 2021
By:
|
/s/ James Sapirstein
|
Name:
James Sapirstein
|
|
Title:
President and Chief Executive Officer
|